By admin 
In a move that has sent shockwaves through the American healthcare landscape, Medicare has proposed a radical restructuring of how it reimburses hospitals for drugs acquired through the 340B drug discount program, signaling a potential financial sea change for safety-net providers across the country. Under the sweeping proposal released on Thursday by the Centers for Medicare & Medicaid Services (CMS), the agency intends to slash payments for these discounted drugs by more than a third, beginning in the 2027 calendar year. The proposal, which is part of the broader annual update to the Hospital Outpatient Prospective Payment System (OPPS), suggests that Medicare pay hospitals for 340B drugs at their average sales price (ASP) minus 33.4%. This represents a dramatic departure from the current reimbursement rate of ASP plus 6%, a margin that many nonprofit hospitals have long relied upon to fund essential services for underserved populations.
The rationale provided by CMS hinges on recent data-gathering efforts intended to address long-standing criticisms regarding the transparency and equity of the 340B program. According to the agency, extensive surveys conducted over the past two years revealed a significant discrepancy between what hospitals pay for these drugs and what Medicare—and by extension, its beneficiaries—are charged. CMS officials stated that in numerous instances, the co-payments made by elderly and disabled patients exceeded the actual acquisition cost of the drug for the hospital. By lowering the reimbursement rate to ASP minus 33.4%, the agency argues it is aligning Medicare payments more closely with the actual costs incurred by providers, thereby reducing the financial burden on patients who are often responsible for a 20% co-insurance payment based on the total Medicare rate.
However, the proposal has immediately drawn fierce condemnation from advocacy groups representing nonprofit, rural, and academic medical centers. These organizations argue that the 340B program was never intended to be a simple pass-through of costs, but rather a mechanism designed by Congress to allow "covered entities" to stretch scarce federal resources as far as possible. By capturing the spread between the discounted purchase price and the standard insurance reimbursement, safety-net hospitals have historically funded a wide array of non-reimbursable services, ranging from free oncology clinics and mobile health vans to subsidized prescription programs and mental health initiatives.
The 340B program, established by the Veterans Health Care Act of 1992, requires pharmaceutical manufacturers to provide outpatient drugs to eligible healthcare organizations at significantly reduced prices as a condition of having their drugs covered by Medicaid and Medicare Part B. To qualify, a hospital must typically serve a high volume of low-income patients, a metric often determined by its Disproportionate Share Hospital (DSH) percentage. Over the last decade, the program has grown exponentially, evolving into a $50 billion-plus market and becoming a central point of contention between the hospital industry and the pharmaceutical lobby.
Critics of the program, including the Pharmaceutical Research and Manufacturers of America (PhRMA) and various conservative think tanks, have frequently characterized 340B as a "black box" that allows wealthy health systems to generate massive profits while providing minimal benefit to the actual patients for whom the discounts were intended. These critics point to the expansion of "contract pharmacy" arrangements, where large retail pharmacy chains partner with 340B hospitals to dispense discounted drugs, often far away from the hospital’s primary service area. The CMS proposal appears to lean into these criticisms, suggesting that the current payment structure has incentivized the utilization of expensive specialty drugs primarily for their high-margin potential rather than purely clinical necessity.
The financial implications of the proposed rule are starkly divided along tax-status lines. Because the 340B program is restricted to nonprofit and government-owned facilities, for-profit hospital chains—which are ineligible for the discounts—stand to benefit from the regulatory shift. Under the "budget neutrality" requirements of the Medicare statute, any savings generated by cutting 340B payments must be redistributed back into the general outpatient payment pool. Consequently, the proposed rule includes a projected 7.4% pay increase for for-profit hospitals in 2027. This redistribution has sparked accusations from the American Hospital Association (AHA) and 340B Health that the government is effectively "robbing the poor to pay the rich," transferring billions of dollars from safety-net providers to corporate-owned health systems and their shareholders.
"This proposal is a direct assault on the mission of safety-net hospitals," said a spokesperson for a coalition of academic medical centers. "By slashing these reimbursements, CMS is ignoring the unique role that 340B hospitals play in caring for the most vulnerable members of society. If this rule is finalized, many of our members will be forced to scale back or eliminate programs that provide life-saving care to patients who have nowhere else to turn. The idea that this is about ‘patient savings’ is a smokescreen for a massive redistribution of wealth within the healthcare sector."
The legal history of 340B reimbursement cuts adds another layer of complexity to the current situation. This is not the first time CMS has attempted to reduce these payments. In 2018, the Trump administration implemented a similar cut, reducing payments to ASP minus 22.5%. That move led to years of litigation, culminating in the 2022 Supreme Court decision in American Hospital Association v. Becerra. In a unanimous ruling, the Court held that the Department of Health and Human Services (HHS) lacked the authority to vary reimbursement rates for 340B hospitals specifically without first conducting a formal survey of hospital acquisition costs. Following that ruling, CMS was forced to revert to the ASP plus 6% formula and eventually issued billions of dollars in back payments to affected hospitals.
In the current proposal, CMS appears to be attempting to "bulletproof" its legal position by citing the comprehensive cost surveys it has conducted since the SCOTUS ruling. By basing the 33.4% reduction on empirical data gathered directly from hospitals, the agency believes it has met the statutory requirements that were previously ignored. Legal analysts suggest that while this makes a successful court challenge more difficult for hospitals, it does not make it impossible. Hospital advocates are already questioning the methodology of the surveys, arguing that they fail to account for the significant administrative overhead and compliance costs associated with participating in the 340B program.
The timing of this proposal comes at a moment of intense financial pressure for the American hospital industry. While many systems have recovered from the immediate shocks of the COVID-19 pandemic, they are now grappling with soaring labor costs, inflation, and a "broken health system" that increasingly rewards scale and consolidation over community-based care. For many rural hospitals, 340B margins are the difference between remaining operational and closing their doors. In many of these communities, the local hospital is not only the sole provider of emergency and specialty care but also the largest employer.
Furthermore, the involvement of private equity in healthcare has added a new dimension to the debate. As private equity firms have acquired physician practices and smaller hospital groups, they have often sought to maximize 340B revenue as a key part of their business model. Some policy experts suggest that the CMS crackdown is partly aimed at cooling the interest of private equity in safety-net infrastructure, ensuring that federal discounts are not being diverted to private investors. However, the collateral damage of such a policy could be devastating for legitimate nonprofit providers who use every cent of their 340B savings to offset the losses they incur from treating Medicaid and uninsured patients.
Patient advocates are also divided on the proposal. Some argue that any policy that reduces out-of-pocket costs for seniors on fixed incomes is a net positive. They highlight stories of patients who, despite being treated at a "discount" hospital, were forced to choose between their medication and their groceries because of high co-insurance. On the other side, advocates for low-income communities worry that the long-term loss of hospital-funded community health programs will far outweigh the modest reduction in individual drug co-pays.
As the 60-day public comment period begins, the healthcare industry is bracing for an intense lobbying battle. Pharmaceutical companies are expected to support the rule, viewing it as a necessary step to curb a program they believe has grown out of control. Meanwhile, hospital associations are mobilizing their members to contact their representatives in Congress, hoping to secure a legislative fix that would override the CMS proposal.
The outcome of this regulatory fight will have profound implications for the future of healthcare delivery in the United States. If the ASP minus 33.4% rate is implemented, it will mark the most significant contraction of the 340B program in its 35-year history. It could lead to a wave of service cuts, hospital consolidations, and a fundamental reassessment of how the nation supports its healthcare safety net. As the debate unfolds, the central question remains: how can the government ensure that drug discounts reach the patients who need them most without bankrupting the very institutions that provide their care? The proposed rule for 2027 suggests that CMS has decided the current balance is unsustainable, but for the nation’s safety-net hospitals, the proposed "fix" may be a bitter pill they simply cannot afford to swallow.
